Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats

Drug Development and Industrial Pharmacy

Volumn 36, Issue 3, 2010, Pages 362-370

  Wu, Lei ^a   Zhang, Ge ^a   Lu, Qin ^a   Sun, Qian ^a   Wang, Mulan ^a   Li, Na ^a   Gao, Zidong ^a   Sun, Ya ^a   Li, Tingting ^a   Han, Deen ^a   Yu, Xue ^a   Wang, Lei ^a   Sun, Wei ^a   Zhao, Di ^a   Wu, Yaning ^a   Lu, Yang ^a   Chen, Xijing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Enteric coated capsule; Oral delivery; Pharmacodynamics; Pharmacokinetics; Salmon calcitonin

Indexed keywords

CITRIC ACID; POLYSORBATE 80; SALCATONIN; SALICYLIC ACID; TAUROCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; HISTOPATHOLOGY; INTESTINE INJURY; INTESTINE MUCOSA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77249169789     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903173580     Document Type: Article

References (33)

1. Lee YH, Sinko PJ. (2000a). Oral delivery of salmon calcitonin. Adv Drug Deliv Rev, 42:225-238
2. Schneyer CR. (1991). Calcitonin and the treatment of osteoporosis. Md Med J, 40:469-473
3. Sinswat P, Tengamnuay P. (2003). Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: Comparison with hydroxypropyl and dimethyl-cyclodextrins. Int J Pharm, 257:15-22.
4. Youn YS, Kwon MJ, Dong HN, Su YC, Lee S, Lee KC. (2008). Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection. J Control Release, 125:68-75.
5. Stevenson JC, Evans IM. (1981). Pharmacology and therapeutic use of calcitonin. Drugs, 21:257-272
6. Reginster JY, Jeugmans AM, Sarlet N, McIntyre HD, Franchimont P. (1992). The effect of nasal hCT on bone turnover in Paget's disease of bone-implications for the treatment of other metabolic bone diseases. Br J Rheumatol, 31:35-39
7. Zhou XH. (1994). Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J Control Release, 29:239-252
8. Guggi D, Krauland AH, Bernkop-Schnurch, A. (2003). Systemic peptide delivery via the stomach: In vivo evaluation of an oral dosage form for salmon calcitonin. J Control Release, 92:125-135
9. Guggi D, Bernkop-Schnurch A. (2003). In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases. Int J Pharm, 252:187-196
10. Song KH, Chung SJ, Shim CK. (2005). Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release, 106:298-308.
11. Sinko PJ, Smith CL, McWhorter LT, Stern W, Wagner E, Gilligan JP. (1995). Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides: Administration of recombinant salmon calcitonin in rats. J Pharm Sci, 84:1374-1378
12. Hastewell J, Lynch S, Williamson I, Fox R, Mackay M. (1992). Absorption of human calcitonin across the rat colon in vivo. Clin Sci, 82:589-594
13. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. (2008). Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release, 125:236-245
14. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quioá E, Alonso MJ. (2006). Chitosan-PEG nanocapsules as new carriers for oral peptide delivery: Effect of chitosan pegylation degree. J Control Release, 111:299-308.
15. Basan H, Gu M, Tevfik M. (2006). Release characteristics of salmon calcitonin from dextran hydrogels for colon-specific delivery. Eur J Pharm Biopharm, 143:234-246
16. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. (2005). A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci, 25:133-143
17. Veronese FM, Pasut G. (2005). PEGylation, successful approach to drug delivery. Drug Discov Today, 10:1451-1458
18. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. (2004). pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release, 98:1-9.
19. Swenson ES, Milison WB, Curatolo W. (1994). Intestinal permeability enhancement: Efficacy, acute local toxicity, and reversibility. Pharm Res, 11:1132-1142
20. Quan Y, Hattori K, Lundborg E, Fujita T, Murakami M, Muranishi S, et al. (1998). Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. Biol Pharm Bull, 21:615-620
21. Michael S, Thole M, Dillmann R, Fahr A, Drewe J, Fricker G. (2000). Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. Eur J Pharm Sci, 10:133-140
22. Pagani G, Pagani MD, Gianola D, Pedroncelli A, Cortesi L, Gheradi F, et al. (1991). Hypocalcemic effects of rectal and intramuscular administration of synthetic salmon calcitonin. Int J Clin Pharmacol Ther Toxicol, 29:329-332
23. Lee YH, Makhey V, Yu H, Hu P, Perry B, Sutyak JP, et al. (2000b). Pharmacokinetics and disposition of salmon calcitonin in beagle dogs. Eur J Pharm Biopharm, 23:264-275
24. Fetih G, Habib F, Okada N, Fujita T, Attia M, Yamamoto A. (2005). Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu1,7]-eel calcitonin in rats. J Control Release, 106:287-297
25. Marcos GF, Torres D, Alonso MJ. (2005). New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm, 296:122-132
26. Sakuma S, Ishida Y, Sudo R, Suzuki N, Kikuchi H, Hitawari K, et al. (1997). Stabilization of salmon calcitonin by polystirene nanoparticles having surface hydrophilic polymeric chains against enzymatic degradation. Int J Pharm, 159:181-189
27. Dohi M, Nishibe Y, Makino Y, Suzuki Y. (1993). Enzymatic barrier to nasal delivery of salmon calcitonin in rabbits. Proceedings of the international symposium control on relative society, Kyoto, Japan, 9.
28. Mackay M. (1991). Delivery of recombinant peptide and protein drugs. Biotechnol Genet Eng Rev, 8:251-278
29. Lee YH, Perry BA, Labruno S, Lee HS, Stern W, Falzone LM, et al. (1999). Impact of regional intestinal pH modulation on absorption of peptide drugs: Oral absorption studies of salmon calcitonin in beagle dogs. Pharm Res, 16:1233-1239
30. Takatsuka S, Takahiro M, Atsushi K. (2006). Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Int J Pharm, 316:124-130
31. Swenson ES, Curatolo W. (1992). Intestinal permeability enhancement for proteins, peptides, and other polar drugs: Mechanisms and potential toxicity. Adv Drug Deliv Rev, 8:39-92.
32. Yamamoto A, Uchiyama T, Nishikawa R, Fujita T, Muranishi S. (1996). Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: Effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J Pharm Pharmcol, 48:1285-1289
33. Oberle RL, Moore TJ, Krummel DA. (1995). Evaluation of mucosal damage of surfactants in rat jejunum and colon. J Pharmacol Toxicol Methods, 33:75-81.